MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancer

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in HR+, HER2- advanced breast cancer

LBA6_PR - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer George Sledge, US Recorded Sunday, September 29, at ESMO 2019 Press briefing 2: Breast Cancer. More info: http://oncoletter.ch